Celldex Therapeutics, Inc.
CLDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000744218
No open-market purchases or sales by Celldex Therapeutics, Inc. insiders were filed in the last 90 days; 253 institutions reported holding it in 13F filings for Q2 2026, worth $3.16B in total; no superinvestor holds it.
Superinvestors holding CLDX, Q2 2026
No superinvestor reported holding CLDX in Q2 2026.
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of CLDX each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q3 2022
0 superinvestors holding at quarter end
- Sold out
- Viking Global Investors
Q2 2022
1 superinvestor holding at quarter end
- Added
- Viking Global Investors (+26.6%)
Q1 2022
1 superinvestor holding at quarter end
- Added
- Viking Global Investors (+143.7%)
Q4 2021
1 superinvestor holding at quarter end
- Reduced
- Viking Global Investors (−0.6%)
Q3 2021
1 superinvestor holding at quarter end